Recent Progress in the Management of Retroperitoneal Sarcoma by Cheifetz, Rona et al.
Correspondence to: Dr Carol J Swallow, 600 University Avenue, #1224, Toronto, Ont., Canada M5G 1X5. Tel: (+1) 416-586-1558; Fax: (+1)
416-586-8392; E-mail: cswallow@mtsinai.on.ca
1357± 714X print/1369± 1643 online/01/010017± 10 ½  2001 Taylor & Francis Ltd
DOI: 10.1080/13577140120048908
Sarcoma (2001) 5, 17± 26
ORIGINAL ARTICLE
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Abstract
Retroperitoneal sarcomas (RPS) are rare tumours that typically present late and carry a poor prognosis even following grossly
complete resection. In an attempt to improve the outlook for patients with RPS, sarcoma specialists have employed various
adjuvant  therapies,  including extermal beam  radiation,  intraoperative  radiation,  brachyradiation  and  systemic  chemo-
therapy. This article reviews the presentation and prognosis of RPS, and focuses on the results of new treatment strategies
compared with conventional management.
A Medline search of the English literature was performed to identify all retrospective and prospective reports relating to the
management of adult RPS published since 1980. Series that did not analyse RPS separately from other intra-abdominal or
extra-abdominal sarcomas or other malignancies were excluded, and information on investigation, presentation, prognostic
factors, treatment and outcome was extracted from the remaining reports. Survival and local control data were collected from
reports that contained at least 30 cases of RPS (n = 31).
While surgical resection remains the cornerstone of treatment for RPS, the majority of patients will relapse and die from
sarcoma within 5 years of resection. Adjuvant radiation may improve these results, but further trials are required to defini-
tively demonstrate its benefit. Possible reasons for the failure of conventional treatment are discussed, and alternative strat-
egies designed to overcome these obstacles are presented.
Introduction
Adult soft tissue sarcoma presents in five principal
sites,  with  the  retroperitoneum  being  the  least
common (Fig. 1). While advances in the local man-
agement of extremity sarcoma with combined surgery
and  radiotherapy  have  improved  long-term  local
control rates from less than 80% in 1980 to as high as
95% presently,1,2 the local failure rate for retroperi-
toneal sarcoma (RPS) remains high. The effective-
ness  of  both  surgery  and  radiotherapy  is
compromised  by  the  tendency  of  retroperitoneal
tumours to grow silently until they involve adjacent
critical and sensitive structures. Predictably, the local
control and survival rates for RPS are much worse
than for sarcomas arising at other sites (Fig. 2).
In most modern series, fewer than 70% of RPS are
resected with curative intent at presentation, and at
least one-half of the patients who have a grossly com-
plete resection develop a local recurrence (Table 1).
The majority of deaths in patients with RPS are due
to complications of uncontrolled intra-abdominal dis-
ease, rather than to distant metastatic disease.3± 5 This
suggests that strategies to improve local control could
reduce  disease-related  morbidity,  improve  disease-
free survival, and possibly improve the cure rate. Since
complete gross resection is the only treatment factor
definitively shown to improve survival in RPS,3,4,6± 9
several authors have advocated more aggressive en bloc
resection of the tumour together with adherent organs
and structures. The effectiveness of such a surgical
Fig. 1. The frequency of sites of presentation for soft tissue sar-
coma. Data are from a prospective database of all soft tissue sar-
comas seen in the Princess Margaret Hospital multidisciplinary 
sarcoma clinic from 1988 to 1997 (n = 1282).18 R. Cheifetz et al.
Table I. Treatment outcome for retroperitoneal sarcomaa
Reference n Complete Overall Survivalc Local control after 
resection rateb 
(%)
5 year (%) 10 year (%) complete resectiond (%)
Petersen et al.e (in press)44 87 nr 47 nr 58
Alektiar et al.e (2000)33 32 nr 45 nr 63
Ero lu et al.f (1999)24 40 85 49g nr 45 @ mean 57 months
Herman et al. (1999)49 70 73 53g 40g nr
Malerba et al.h (1999)50 42 60 48g nr nr
Lewis et al.i (1998)4 500 62 54h 35h 59h
Wang et al.h (1996)25 40 70 25 21 nr
Jenkins et al. (1996)26 119 49 20 nr nr
Karakousis et al. (1995)21 90 96 63 46 50 @ min. 5 years, 40 @ min. 10 
years
Kilkenny et al.h (1996)27 63 78 48 37 nr
Singer et al. (1995)28 83 nr 60 50 nr
Wang et al.j (1994)32 30 60 14 nr nr
van Doorn et al. (1994)51 34 88 35g nr 37
Catton et al. (1994)19 104 43 36 14 50 @ 5 years, 18 @ 10 years
Sindelar et al.k (1993)35 35 80 45g nr 37 @ 8 years
Shiloni et al.l (1993)52 41 56 45 33 10 @ 10 years
Zornig et al. (1992)53 51 59 35 15 nr
Alvarenga et al. (1991)3 120 30 29 nr 15
Dalton et al. (1989)7 116 54 40 22 41 @ mean 4.1 years
Pinson et al.h (1989)54 79 48 44 nr nr
Bolin et al. (1988)16 32 62 28 nr nr
Salvadori et al.h (1986)55 43 42 11 nr nr
Karakousis et al. (1985)56 68 40 34 22 nr
Glenn et al. (1985)10 37 72 23g nr nr
Wist et al.h (1985)57 36 43 22 nr nr
McGrath et al.h (1984)9 47 38m 32 19 44 @ median 5 years
Shmookler & Lauern (1983)58 36 nr 34 27 nr
Stower & Hardcastleh (1982)59 32 35 nr nr nr
Cody et al.o (1981)20 80 66 45g nr 23
Storm et al. (1981)5 54 61 33 10 28
Fortner et al.p (1981)60 78 53 37g  nr nr
nr, Not reported.
a Series of 30 or more patients published in English since 1980. All series are retrospective except for Petersen et al.,
Alektiar et al., Lewis et al., Jenkins et al., Sindelar et al., and Glenn et al. Where the same centre has published sequential series
that include patients all included in a previous series, only the most recent qualifying publication is quoted.
b The proportion of patients with retroperitoneal sarcoma undergoing surgical exploration at that centre who had a grossly
complete resection, irrespective of the microscopic margin status. The denominator used to calculate this proportion does
not always correspond to n, the number of patients included in the series.
c Irrespective of resection status, unless otherwise noted. Actuarial except for Sindelar et al., where the survival rate is
actual.
d Locoregional control rate in patients undergoing complete resection, with or without the use of adjuvant radiotherapy
or chemotherapy. Unless otherwise indicated, the figure quoted is actuarial and at 5 years post-resection.
e All patients received intraoperative radiotherapy; the majority also received external beam radiotherapy. For Alektiar et
al., survival rate is quoted for 32 patients, 30 of whom had complete resection.
f Eleven patients received hyperthermic total abdominal perfusion.
g Survival quoted for completely resected patients only.
h Limited to patients with primary tumours.
i Complete resection rate is quoted for patients with primary or recurrent disease excluding those with distant metastases
(n = 397); survival rates quoted are disease-specific survival in all patients with primary disease (n = 278); local control rate
quoted is for patients with primary disease undergoing either complete (n = 185) or partial (n = 62) resection.
j Limited to patients with locally recurrent disease.
k Prospective randomized trial of post-operative radiotherapy with or without intraoperative radiotherapy for completely
resected patients; survival and local control rates quoted for both arms combined.
l Limited to patients with high-grade tumours.
m Complete resection defined as microscopic margins negative.
n Limited to patients with leiomyosarcoma.
o Rates quoted for patients treated since 1971.
p Included eight paediatric rhabdomyosarcomas.Management of retroperitoneal sarcoma 19
approach in improving long-term disease control is,
however, difficult to prove.
Post-operative radiotherapy is frequently given for
RPS, but there are significant barriers to its efficacy.
Accurate  determination of  the  radiation  treatment
volume may be compromised by incomplete docu-
mentation of the extent of disease. In addition, the
radiation dose is usually limited to less than 50 Gy
both by sensitive critical structures in the field and by
the size of the treatment volume needed.10 Not sur-
prisingly, there is no clear evidence that post-opera-
tive radiation significantly reduces the risk of local
recurrence after a grossly complete resection. How-
ever, post-operative radiation may delay the time to
recurrence (Fig.  3),  suggesting that  external beam
radiation might be effective if an adequate dose could
be given to the tissues at risk. This has prompted an
interest  in  other  strategies  for  adjuvant  radiation
delivery, including pre-operative external beam radi-
ation,  intraoperative  radiation  therapy,  and  post-
operative  brachytherapy.  The  addition  of  systemic
chemotherapy is another strategy undergoing evalua-
tion in some centres.
Our understanding of RPS is based largely on ret-
rospective  single-institutional  experiences,  which
usually report on small numbers of patients who were
treated non-uniformly over several decades. Limited
patient  numbers  and  great  variability  in  extent  of
local disease make it difficult to conduct meaningful
randomized clinical trials, and even non-randomized
prospective trials are rare. In this review, we briefly
describe the presentation, natural history, diagnosis,
and investigation of patients with RPS, and focus on
the results of treatment as documented in the modern
literature.  New  treatment  strategies  are  presented
and the need for centralized, multidisciplinary care as
well as for multicentre collaboration in conducting
prospective trials is emphasized.
Presentation and natural history
According to population-based data from the Sur-
veillance,  Epidemiology  and  End  Results  (SEER)
Program,11 the age-adjusted annual incidence of all
soft tissue sarcomas (excluding epidemic Kaposi’s) is
about 5 per 100,000 in the United States. According
to the SEER data, RPS accounted for 10% of sarco-
mas  arising  in  all  sites  (1602  of  16,067  cases,
Kaposi’s sarcoma excluded). RPS had an equal inci-
dence in males and females, and a  median age  at
presentation of 61.5 years.11 Most large case series of
RPS concur with these demographic data. There are
few recognized aetiologic factors for soft tissue sar-
coma. These include the development of radiation-
induced tumours, and sarcomas arising in patients
with  known  genetic  mutations,  such  as  malignant
peripheral nerve sheath tumours in neurofibromato-
sis, and various types of soft tissue sarcoma in the Li±
Fraumeni syndrome.12
RPS usually arise from the connective tissues pos-
terior to the posterior peritoneum, and uncommonly
from specific retroperitoneal tissues such as the kid-
ney,  inferior  vena  cava,  spinal  nerve  roots  or  the
aorta.13,14 RPS often grow silently to a very large size
before  diagnosis.  Patients  typically  present  with
chronic non-specific complaints related  to  tumour
compression  rather  than  infiltration,15  including
abdominal distension and pressure, early satiety and
anorexia,  changes  in  bowel  or  bladder  habit,  and
peripheral oedema. Not infrequently, the diagnosis is
made on an incidentally found asymptomatic mass.16
Cross-sectional imaging may demonstrate a massive
tumour markedly displacing intra-abdominal organs
(Fig. 4), and the lack of associated symptoms implies
that  the  patient  has  adapted  to  indolent  tumour
growth. Patients with high-grade tumors may present
with a rapidly growing abdominal mass, pain or more
severe constitutional symptoms, particularly  in the
presence of metastatic spread. This constellation of
symptoms may also represent the development of de-
differentiated areas in an otherwise apparently well-
differentiated liposarcoma.17
Fig. 2. Site-specific survival in patients with soft tissue sar-
coma. Overall survival from the time of diagnosis is shown for
patients treated with curative intent at The Princess Margaret
Hospital for soft tissue sarcoma of the extremity, trunk, or head
and neck (1980± 1988), and retroperitoneum (1975± 1988)
(modified from References 1 and 19, with permission).
Fig. 3. Effect of post-operative radiation on time to recurrence
in  RPS.  The proportion  of  patients remaining  free of  infield
recurrence from the time of diagnosis is shown for 45 patients
with RPS treated with grossly complete resection and post-oper-
ative external beam radiation. Patients are grouped according to
the dose of radiation given, as indicated (from Reference 19,
reproduced with permission).20 R. Cheifetz et al.
Between 10  and 20%  of  patients  with  RPS  are
found to have distant metastases at the time of initial
presentation. Of those who present with non-meta-
static disease and undergo curative  therapy, about
25% will develop metastases, most commonly in the
liver and lungs.4,5 This metastatic rate is unexpect-
edly low considering the high proportion of patients
who present with very large tumours and who do not
achieve local control. Whether RPS is associated with
an inherently limited metastatic potential or whether
the incidence of metastases is under-reported is not
clear. Local  and  systemic recurrences can  develop
late: in one large series, 14% of all failures occurred
5± 12  years  after  diagnosis.18  This  highlights  the
importance  of  long-term  follow-up  after  curative
therapy for these patients.
The various histologic subtypes of adult RPS are
presented in Table 2. As in most recent series, the
three most common histologies (liposarcoma, leio-
myosarcoma  and  malignant  fibrous  histiocytoma)
accounted for about 70% of the total RPS reported in
the SEER study. Overall, 36± 50% of RPS are scored
as low grade, in contrast to 19± 26% of extremity and
truncal sarcomas.1,3± 5,7,19± 21 This could explain the
lower incidence and/or delayed appearance of metas-
tases in patients with RPS.
Diagnosis and pretreatment evaluation
Computerized axial tomography (CT) is particularly
useful  in  the  diagnosis,  staging  and  pretreatment
planning of RPS.22 Encasement of major vessels and
involvement of adjacent organs, as well as identifica-
tion of lung and liver metastases, are of particular
interest. Ultrasound and magnetic resonance imag-
ing (MRI) are useful complements to CT in charac-
terizing liver lesions, while MRI gives more detailed
information  about  neurovascular  and  muscular
involvement.
Characteristics  of  retroperitoneal  tumours  that
predict for  malignancy on CT  are  size  >  5.5  cm,
absence  of  calcifications,  irregular  margins,  and
cystic degeneration or necrosis.23 Fatty tumours are
readily identified on CT by their low attenuation, and
Fig. 4. Displacement of viscera by tumour pre-operatively. A patient with a large right-sided RPS that displaces the liver, bowel, and 
the ipsilateral kidney.
Table 2. Frequency of histological subtypes of retroperitoneal 
sarcoma*
Histology Frequency (%)
Liposarcoma 30.0
Leiomyosarcoma 26.7
Malignant fibrous histiocytoma 14.9
Sarcoma not otherwise specified 9.4
Fibrosarcoma 4.5
Malignant neurilemmoma 2.6
Neurofibrosarcoma 2.1
Malignant mesenchymoma 2.0
Rhabdomyosarcoma (excluding embryonal) 1.9
Malignant hemangiopericytoma 1.2
Hemangiosarcoma 0.7
Myxosarcoma 0.3
Malignant hemangioendothelioma 0.09
Epithelioid sarcoma 0.09
* From SEER.11Management of retroperitoneal sarcoma 21
the  presence  of  high  attenuation  areas  in  a  fatty
tumour may indicate that de-differentiation has taken
place.  CT-Guided  percutaneous  needle  biopsy  of
these areas may provide confirmation.
The pretreatment evaluation of a patient with pos-
sible  RPS  should  include:  (i)  a  general  medical
assessment; (ii) biopsy with histologic classification
and  grading;  (iii)  a  thorough  evaluation  of  local
tumour extent; and (iv) a metastatic search, with par-
ticular attention to the lungs and liver. A radio-iso-
tope  differential  renal  function  scan  is  useful  for
evaluating the function of the contra-lateral kidney
when en bloc resection of the homolateral kidney is
contemplated.
The  amount  of  tissue  obtainable  from  an  open
biopsy  usually  provides  the  pathologist  the  best
opportunity to fully classify and grade the sarcoma
prior  to  treatment.  However,  an  open  biopsy  is
potentially  morbid,  and  may  delay  treatment.  In
addition, the peritoneal cavity may become contami-
nated with tumour. CT-guided needle biopsy carries
a lower potential for morbidity and, when performed
with the posterior approach, has a low risk of contam-
inating  uninvolved  areas.  In  our  centre,  we  have
found CT-guided core needle biopsy to be safe and
efficacious in making a tissue diagnosis of retroperi-
toneal  tumours. The  interpretation of  small  tissue
specimens can be difficult, however, and we recom-
mend that both the biopsy procedure and the patho-
logical  evaluation  be  carried  out  in  centres  with
experience in managing soft tissue sarcomas. Ideally,
pathological  evaluation  of  the  biopsy  specimen
should not only confirm the diagnosis of sarcoma,
but also provide the histological subtype and grade.
In practice, we accept the diagnosis of sarcoma NOS
(not  otherwise  specified)  as  sufficient to  plan  and
undertake therapy. If the diagnosis cannot be made
despite a second CT-guided biopsy, an open biopsy
is usually required. This biopsy should be planned
with the eventual resection in mind, and executed so
as to minimize contamination of uninvolved tissues.
Outcome: patterns of failure and prognostic 
variables
Table 1 presents patient outcome as quoted in all
individual series of 30 or more cases of adult RPS
published in English since 1980 (n = 31). Series that
do not separate RPS from intra-abdominal sarcomas
or other miscellaneous tumours have been excluded.
Where  the  same  centre  has  published  sequential
series that include patients all included in a previous
series, only the most recent qualifying publication is
included.
As shown in Table 1, the overall survival reported
for patients with RPS varies from 11 to 63% at 5
years, and from 10 to 50% at 10 years following ini-
tial presentation. The wide spectrum of survival rates
is at least partially due to differences in the patient
population  making  up  the  denominator  in  each
study. Failure to control local disease is a contribut-
ing factor towards death in almost 90% of patients,
and is due either to an inability to completely resect
the primary or to local relapse following total gross
resection. A variety of potential prognostic variables
have been investigated.
Complete resection
The only treatment factor that consistently predicts
for  improved survival  is  a  grossly  complete  tumor
resection, and complete resection rates are typically
reported as under 70%. Survival rates at 5 and 10
years after complete resection are approximately 60
and 25%, respectively. Recent improvements in pre-
operative assessment, and a more aggressive surgical
approach to include resection of involved viscera and
other structures, have improved complete resection
rates to 80± 95% in some series. Karakousis et al.21
report a complete gross resection rate of 96%, and
associated 5-  and 10-year  survival rates of 63  and
46%. Some of this improvement is a result of better
pretreatment selection of patients for surgical explo-
ration, but it is likely that there has also been a real
increase in complete resection rates.
Size
Tumour size has generally not been shown to influ-
ence  survival,  local  failure  or  distant  failure  rates.
This reflects the fact that RPS are almost always very
large at presentation, most being larger than 10 cm in
diameter,4,24,25 so that no series includes a sufficient
number of smaller tumours to demonstrate an effect
on outcome.
Grade
High grade predicts for decreased survival in many
series,3,4,6± 8,10,20,21,24,26± 29  but  not  in  oth-
ers.18,19,30,31 In one large series,18 high grade pre-
dicted for increased metastatic failure 5 years or more
after initial presentation, but not for an increased risk
of mortality. The development of metastatic disease
in long-term survivors of RPS may represent de-dif-
ferentiation of low-grade disease after many years.
Histology
Most series are too small to meaningfully evaluate the
effect  of  histological  subtype  on  prognosis.  Some
series have shown improved survival in patients with
liposarcoma  compared  with  the  other  histologies
(univariate analysis only),19,27 but not an improved
local relapse free rate.19 This may reflect the generally
more indolent growth pattern of liposarcoma. In a
large prospective series, Lewis et al.4 recently reported
no independent effect of histology on survival in a22 R. Cheifetz et al.
multivariate analysis, although liposarcoma histology
predicted for an increased risk of local recurrence. It
seems likely that the retroperitoneal site is itself the
predominant  determinant  of  outcome,  rather  than
histological subtype.
Local failure
Retreatment of local relapse is generally associated
with poorer survival, even with aggressive resection.
Karakousis et al.21 reported 10-year survival rates of
57%  for  primary  tumours  versus  26%  for  locally
recurrent tumours. Lewis et al.4 reported 5-year dis-
ease-specific survival rates of 54 and 22% for patients
presenting with primary disease and local recurrence,
respectively. In the latter series, those who developed
local  relapse after complete resection of a primary
tumour had a median survival of only 28  months.
Wang  et  al.32  reported a  12%  survival  rate  at  96
months for patients with completely excised recur-
rent tumours, again indicating that the long-term sal-
vage  rate  is  quite  low  for  recurrent  RPS.  Local
control rates are similarly compromised in patients
presenting with recurrent disease, due at least in part
to lower complete resection rates, but probably also
as a result of unfavourable biology.21,33
Adjuvant radiation
In some series (retrospective, non-randomized), treat-
ment  with  external  beam  radiation  after  complete
resection  has  apparently  been  associated  with
improved outcome. One report showed an improve-
ment in actuarial 10-year  local relapse free survival
from  35  to  55%  in  unirradiated  versus  radiated
patients  following  complete  resection.18  In  a  small
series, Tepper et al.34 reported improved local control
for patients who received more than 60 Gy compared
with less than 50 Gy. Fein et al.31 reported local con-
trol rates of 72% versus 38% in patients who received
more versus less than 55 Gy; these rates were meas-
ured  at  2  years  post-treatment.  Catton  et  al.19
reported a similar differential in local control rates at
2 and 5 years for patients who received greater or less
than 35 Gy following complete excision; by 10 years,
however, the local relapse rates had reached equiva-
lence. In a randomized trial designed to test the effect
of additional intraoperative radiotherapy in patients
who all received external beam postoperatively, Sinde-
lar  et  al.35  found that  an  intraoperative  boost  that
brought the total  dose to 60  Gy  reduced the  local
relapse rate from 80 to 40% (p < 0.05) at 8 years.
However, there was no difference in overall or disease-
free survival rates between the two treatment arms.
Overall, the available evidence suggests that low-
dose postoperative radiation is of little benefit in pre-
venting local  relapse, and that  increasing the dose
delays but does not prevent local recurrence in the
majority  of  patients.  Furthermore,  post-operative
radiation is clearly associated with significant risk of
severe acute and late bowel toxicity.10
Adjuvant chemotherapy
The evidence for the routine use of adjuvant chemo-
therapy in localized, resectable soft tissue sarcoma is
controversial. Individual randomized trials have not
shown  a  conclusive  benefit,  but  a  recent  meta-
analysis36 of 1568 patients with localized, resectable
soft  tissue sarcomas at  various sites indicated that
doxorubicin-based  chemotherapy  was  associated
with  a  significant  delay  in  both  local  and  distant
relapse. There was a trend towards an improvement
in overall survival, but it did not reach statistical sig-
nificance. Patients with RPS were not identified sep-
arately in the analysis. A small randomized trial of
adjuvant  chemotherapy for  RPS10  showed inferior
survival and severe treatment toxicity for the patients
receiving chemotherapy.
New treatment strategies
The importance of achieving complete gross resection
of RPS has been emphasized. At major sarcoma cen-
tres, the following strategies are currently employed to
optimize  complete  resection  rates:  (i)  detailed  pre-
operative assessment with the routine use of cross-sec-
tional imaging and needle biopsy to improve patient
selection;  (ii)  aggressive  surgery  to  include  en  bloc
resection  of  involved  viscera  and  other  expendable
structures; and (iii) improved specialized post-opera-
tive care and rehabilitation. These tactics have resulted
in reported resection rates as high as 95%, with low
perioperative mortality.  It  is  not  altogether clear to
what extent these high resection rates reflect improve-
ments in pre-operative patient selection rather than in
overall  resectability.  Over  a  recent  3-year  period
(1996± 1998), 25 patients with RPS were referred to
our centre with a tumour in situ. Five had metastases
at  presentation,  three were considered unresectable
after investigation, and two declined any therapy. The
remainder underwent complete resection, for an over-
all resectability rate of 60%, and a total gross resection
rate of 100% in those selected for operative explora-
tion. Seventy-eight percent of the latter group required
en bloc resection of adjacent viscera. There is probably
a  selection bias  for  adverse features in the  patients
referred to our centre. Nevertheless, our recent experi-
ence suggests that the current surgical approach has
increased overall resection rates.
Post-operative  radiation  therapy  is  the  standard
adjuvant treatment for extremity sarcoma, but it is not
effective in preventing local recurrence of RPS. Possi-
ble reasons for this include the use of inadequate radi-
ation doses, inadequate treatment volumes, or both.
The presence of adhesed small bowel in the tumour
bed post-operatively impedes the delivery of a full rad-
ical  dose  (Fig.  5).  Strategies  to  improve  radiationManagement of retroperitoneal sarcoma 23
delivery and to escalate  the  total  dose of  radiation
include  pre-operative  radiotherapy,  intraoperative
placement of tissue expanders to displace the small
bowel out of the post-operative radiation field,37 and
use  of  brachyradiation  or  intraoperative  electron
beam techniques.35,38± 43 The latter strategies may be
employed in conjunction with conventional external
beam radiotherapy to escalate the dose to the tumour
bed. Radiation targeted specifically at the tumour bed
may be delivered intraoperatively (intraoperative radi-
ation therapy (IORT)) with an electron beam directed
through an appropriately positioned cone, or with a
high dose rate brachytherapy applicator,33 or it may
be administered in the post-operative period with low
dose rate or pulsed dose rate brachytherapy through
intraoperatively placed catheters.39
The  experience  with  IORT  for  RPS  has  been
mixed.  Gieschen  et  al.40  recently  reported  very
impressive local (91%) and distant (80%) 5-year con-
trol rates in 16 patients who received electron-beam
IORT after pre-operative external beam therapy and
complete gross resection with moderate morbidity.
Using  post-operative  external  beam  radiation  plus
electron-beam IORT, Bussieres et al.38 found a 2-
year  relapse free rate of 60%,  with acute  and late
complication rates of 21 and 31% respectively. Ale-
ktiar et al.33 reported the Memorial Sloan± Kettering
experience with high dose rate IORT given with or
without external beam therapy for 32 patients. In this
recent series, the overall 5-year local control rate was
74% for patients presenting with primary disease and
54% for those with recurrent tumours. A 58% local
control  rate  was  found  by  Petersen  et  al.44  in  87
patients  treated  at  the  Mayo  clinic  with  electron-
beam IORT and external beam therapy. Peripheral
neuropathy and hydronephrosis appear to be signifi-
cant sources of long-term morbidity following retro-
peritoneal IORT.40,42,44
A randomized study of post-operative radiotherapy
with or without an intraoperative boost did not show
a significant benefit for dose escalation in the post-
operative setting.35 This trial had insufficient power
to detect small differences in outcome, but the intra-
abdominal relapse rate was very high in both study
arms. It is possible that some patients did not benefit
from dose escalation because the treatment volumes
were not adequate to cover all the areas at risk. This
hypothesis is supported by the findings of Sugarbaker
et al.45 who reported the patterns of failure after sur-
gery  for  RPS.  Recurrences  were  identified  as
expected in the tumour bed and in sites of previous
tumour  involvement,  but  also  in  sites  of  surgical
trauma and in nodules studding the peritoneal sur-
face. The number of sites of relapse increased with
the number of operations performed. This observa-
tion supports the theory that intra-abdominal tumour
emboli are frequent at the time of primary surgery,
and  that  these  emboli are  released at  resection to
become entrapped in fibrinous material along narrow
resection  margins  and  at  other  sites  of  surgical
trauma. The complex cytokine and protease cascades
involved in wound healing may further contribute to
the establishment of tumour emboli diffusely in the
peritoneal and retroperitoneal spaces.
Fig. 5. Comparison of the radiation field pre- and post-operatively. Pre- and post-operative CT scans of a patient with a right-sided 
RPS are shown in the left- and right-hand panels, respectively. The post-operative film demonstrates that the previously displaced bowel 
has fallen back into the tumour bed after resection of the tumour and right kidney.24 R. Cheifetz et al.
Tumour resection may thus expand the areas at
risk of failure well beyond the tumour bed. Accurate
identification and effective  treatment  of  the  target
volume with post-operative radiation is clearly prob-
lematic.  Treating  patients  with  the  tumour  in  situ
provides  the  major  advantage  of  having  cross-sec-
tional imaging available to plan the radiation fields
directly onto the  tumour. In addition, the tumour
mass acts as a tissue expander displacing sensitive
structures out of the radiation field (Figs. 4 and 5),
and very large volumes can be treated to 45 or 50 Gy
with  minimal  acute  toxicity.39,43,46  Pre-operative
external beam therapy may also decrease the risk of
tumour implantation at  resection by sterilizing the
operative field of microscopic tumour emboli prior to
resection.
Another potentially beneficial strategy is to escalate
the dose of radiation delivered to the tumour bed. We
have reported dose escalation to 70 Gy using pre-
operative external beam radiation and post-operative
pulsed  dose  rate  brachytherapy  in  13  completely
resected patients.  Severe duodenitis, the  most fre-
quent acute side effect, was seen in 35% of patients
treated  with  this  combined  therapy  regimen.  The
majority of patients responded to medical manage-
ment and 86% were symptom free by 90 days after
therapy.39
Based on the rationale already outlined and on the
recent experience of our group and others, we feel
that pre-operative radiation is the preferable method
of delivering adjuvant external beam radiotherapy for
RPS. It is better tolerated, it permits the radiation to
be directed more precisely to the tissues at risk, and it
may reduce the risk of tumour implantation at resec-
tion. It appears that dose escalation to the tumour
bed with brachytherapy catheters or IORT may be
given relatively safely following pre-operative radia-
tion, but clinical trials with larger patient numbers
and long-term follow-up are required to determine
the true morbidity and whether this approach will in
fact improve local control.
Pre-operative chemotherapy has been proposed as
an adjunct to surgery and radiotherapy to improve
resectability, and to reduce the risk of local and sys-
temic relapse. Robertson et al.47 reported a trial of
pre-operative  radiotherapy  with  the  radiosensitizer
iododeoxyuridine  in  16  patients  with  locally
advanced RPS. This combined therapy was well tol-
erated, and was associated with a complete resection
rate of 50% and a 2-year local relapse-free rate of
46%.  Sugarbaker48  has  proposed  post-operative
intraperitoneal adriamycin as a method of reducing
local recurrence, and Ero lu et al. recently reported
initial  favourable results with intraoperative  hyper-
thermic total abdominal perfusion in 11 patients.24
The sarcoma group at MD Anderson is investigating
the use of an intensive pre-operative chemoradiation
regimen with the goal of improving resectability, and
reducing the risk of local and systemic failure.61
Conclusion
Better patient selection and more aggressive en bloc
tumour resection have resulted in improved complete
resection rates for RPS at specialized centres. Never-
theless, the majority of patients managed by resection
alone  will  experience local  relapse. At  the  present
time, most centres treat potentially curable RPS with
combined therapy consisting of resection and irradi-
ation. Post-operative external beam radiation is asso-
ciated with significant morbidity and is not effective
in preventing relapse, but may  delay  it. There are
technical  advantages  to  pre-operative radiation  for
both target delineation and sparing of normal tissue,
but the effectiveness of pre-operative radiation has
not been assessed in a randomized trial. Innovative
strategies to escalate the radiation dose via an intra-
operative or post-operative boost have been tested in
small numbers of patients at various individual cen-
tres with varying results. The role of adjuvant chem-
otherapy  in  RPS  is  under  investigation  at  a  few
centres, but currently remains undefined.
Our present policy is to encourage pre-operative
referral and to enter eligible patients into a phase II
trial of pre-operative radiation with a pulsed dose rate
brachytherapy boost to the tumour bed after com-
plete resection. The use of adjuvant radiotherapy for
patients who present after complete resection is con-
troversial. Our policy is to selectively offer post-oper-
ative  radiotherapy  only  after  an  evaluation  of  the
treatment risks, the likelihood of adequate tumour
coverage, the risk of recurrence, and the likelihood of
salvaging a relapse if the initial treatment fails. It is
usually impossible to identify or cover an adequate
treatment  volume  after  an  unplanned intralesional
excision. The patient who has had a planned, en bloc
excision and a careful pathological assessment may
have well-defined areas of microscopic residual dis-
ease that are marked with surgical clips. Small bowel
in the tumour bed usually limits the dose actually
delivered to less than 50 Gy. Overall, we have con-
cluded  that  post-operative  adjuvant  radiation  is
unlikely to be of significant benefit to patients with
RPS. Patients with a primary tumour that cannot be
completely  resected  are  managed  with  palliative
intent,  using chemotherapy,  radiation  therapy  and
operative intervention as deemed appropriate. The
same approach is generally also adopted in patients
with metastatic disease.
We recommend that patients in whom the diagno-
sis of RPS is suspected should be referred to a multi-
disciplinary  sarcoma  unit  before  resection  is
attempted. Centralized multidisciplinary care allows
the development and concentration of the expertise
necessary to manage RPS appropriately, and ensures
optimal  pre-treatment  investigation.  In  addition,
referral to a specialized sarcoma centre increases the
number of patients available for accrual into clinical
trials. RPS is a rare disease. At initial presentation, up
to 40% of patients do not qualify for treatment withManagement of retroperitoneal sarcoma 25
curative intent, further limiting the pool of patients
who  may  qualify  for  studies  of  adjuvant  therapy.
There is clearly a need for multicentre collaboration
to accrue adequate numbers of patients to clinical tri-
als.
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